Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Pfizer's Feldene (piroxicam)

This article was originally published in The Tan Sheet

Executive Summary

Pfizer's Feldene (piroxicam): FDA's Arthritis Advisory Committee will meet Oct. 11 to consider safety and labeling issues presented in a December 1994 Public Citizen Health Research Group citizen petition requesting the removal from the market of drugs containing piroxicam because of a significantly higher risk of gastropathy compared to other nonsteroidal anti-inflammatory drugs (NSAIDs). On Oct. 12, the committee will examine the adequacy of gastropathy warnings in labeling for NSAIDs as a class. The Oct. 11 meeting will be at the Gaithersburg Holiday Inn starting at 8 a.m. and the Oct. 12 meeting at the Silver Spring Holiday Inn at 8:30 a.m...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084295

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel